Dabigatran is the first of four direct‐acting oral anticoagulants approved to prevent stroke in
adult patients with atrial fibrillation using a fixed two‐dose scheme compared with warfarin …

Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial
fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of …

Background and objective: Dabigatran is a new oral anticoagulant recently approved for the
prevention of stroke or systemic embolism in patients with atrial fibrillation (AF). Based on its …

Dabigatran, administered orally as the prodrug dabigatran etexilate (DE), is a direct
thrombin inhibitor shown to be effective in the prevention of stroke and systemic embolism in …

Background—Renal impairment increases the risk of stroke and bleeding in patients with
atrial fibrillation. In the Randomized Evaluation of Long-Term Anticoagulant Therapy (RELY) …

OBJECTIVE: To review the literature regarding the pharmacokinetic (PK) and clinical
implications of the use of dabigatran in severe renal impairment for stroke prevention in …

Routine laboratory monitoring is currently not recommended in patients receiving dabigatran
despite its considerable variation in plasma concentration. However, in certain clinical …

Background: Renal impairment increases the risk of stroke and bleeding in patients with
atrial fibrillation. In the RE-LY trial dabigatran, with approximately 80% renal elimination …

Objectives: The goal of this study was to analyze the impact of dabigatran plasma
concentrations, patient demographics, and aspirin (ASA) use on frequencies of ischemic …

Dabigatran etexilate (dabigatran) is a direct oral thrombin inhibitor approved for the
prevention of ischemic stroke in patients with nonvalvular atrial fibrillation. Dabigatran has …